Amgen gets approval for osteoporosis drug...

Amgen Inc. (AMGN). U.S. FDA approved on Tuesday the sale of the company’s osteoporosis drug Prolia to help prevent fractures in post-menopausal women just days after the medicine received European approval. Amgen said the drug will be available within the next two weeks and cost $825 per 60 milligram injection based on wholesale acquisition cost.